Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 13/20 | 0.55 |
| ▸ | ITGAV | P06756 | 2/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319930 | 0.94 | ITGB1 (0.61) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL3313216 | 0.86 | ITGB1 (0.50) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4624872 | 0.85 | ITGB1 (0.51) | ITGB1ITGAVITGA4ITGB7LMNA | |
| SCHEMBL4625170 | 0.83 | ITGB1 (0.47) | ITGB1ITGAVABL1KDM4EALDH1A1 | |
| SCHEMBL4625490 | 0.83 | ITGB1 (0.59) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL1030228 | 0.83 | ITGB1 (0.49) | ITGB1ITGAVABL1KDM4EALDH1A1 | |
| SCHEMBL3314608 | 0.81 | ITGB1 (0.46) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4750015 | 0.78 | ITGB1 (0.53) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL4626504 | 0.78 | ITGB1 (0.53) | ITGB1ITGAVITGA4ITGB7ABL1 | |
| SCHEMBL6142440 | 0.78 | ITGB1 (0.42) | ITGB1ITGAVITGA4ITGB7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902045-B1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA SA (BE) | 2011-01-19 | — | — | EP | claimed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | claimed |
| EP-1902045-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB Pharma, S.A. (BE) | 2008-03-26 | — | — | EP | claimed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | claimed |
| WO-2006131200-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA, S.A. (BE) | 2006-12-14 | — | — | WO | claimed |
| EP-1902045-B1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA SA (BE) | 2011-01-19 | — | — | EP | disclosed |
| US-7732614-B2 | 2,6-quinolinyl derivatives, processes for preparing them and their uses | UCB S.A. (BE) | 2010-06-08 | — | — | US | disclosed |
| EP-1902045-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB Pharma, S.A. (BE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | UCB PHARMA S.A. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006131200-A1 | 2,6 QUINOLINYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS MEDICAMENT | UCB PHARMA, S.A. (BE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004775-A1 | 2,6-Quinolinyl derivatives, processes for preparing them and their uses | CYP2D6, UGT1A6, CYP3A4 | ITGB1 4685/4885ITGAV 3968/4885ITGA4 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.